Ibrilatazar is under clinical development by Ability Pharmaceuticals and currently in Phase III for Metastatic Pancreatic Cancer. According to GlobalData, Phase III drugs for Metastatic Pancreatic Cancer have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ibrilatazar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ibrilatazar overview
Ibrilatazar is under development for the treatment of advanced solid tumors including pancreatic cancer, biliary tract cancer, lung carcinoma, endometrial cancer, non-small cell lung cancer, adult and pediatric neuroblastoma, glioblastoma. It is administered orally. The drug candidate targets AKT, PI3K, dihydrofolate reductase (DHFR) and mTORC1/C2 and is developed based on membrane lipid therapy. It was also under development for the treatment of breast cancer and glioma.
Ability Pharmaceuticals overview
Ability Pharmaceuticals (Ability Pharma) is a clinical stage biopharmaceutical company. It focuses on developing oral targeted anticancer compounds that produces autophagy-mediated cytotoxicity in cancer cells. The company’s pipeline product include ABTL0812 which treats pancreatic cancer, endometrial cancer, lung cancer, neuroblastoma, biliary tract cancer and glioblastoma. The company develops new drug candidates through clinical proof-of-concept, to later license them to pharmaceutical companies for further development and marketing. It works in partnership with academic institutions to develop new drug candidates. Ability Pharma is headquartered in Barcelona City, Barcelona, Spain.
For a complete picture of Ibrilatazar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
